Stock Detail
CYCLACEL PHARMACEUTICALS INC
Biotechnology
CYCC @ Yahoo Finance | CYCC Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $0.62 | $0.63 | $0.01 | 2.48% | 0.00 | $0.61 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.60 | $0.59 | 69,235 | 33.62M | 443,864 | -2.07 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 0.65 | 0.63 | 0.61 | 0.59 | 0.57 |
Stock Profile
Cyclacel Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-targeted drugs to treat human cancers and various serious disorders. The company is evaluating seliciclib (CYC202), an orally available cyclin dependent kinase inhibitor, which is in Phase II clinical trials for the treatment of lung cancer. Its product candidates also comprise sapacitabine, an orally available nucleoside analog, which is in phase I clinical trial; and CYC116, an orally-active Aurora kinases inhibitor for the treatment of cancer. In addition, the company has preclinical stage programs for the treatment of cancer, inflammatory kidney disease, HIV/AIDS, and type 2 diabetes. Cyclacel Pharmaceuticals is headquartered in Berkeley Heights, New Jersey.